Combination chemotherapy with Methotrexate, Fluorouracil and Leucovorin in advanced Mycosis Fungoides

Authors

  • L Ataei
  • M Shahidi Dadras
Abstract:

Background: Mycosis fungoides (MF) is a cutaneous T cell lymphoma. There are only palliative treatments in advanced stages with no cure. Most chemotherapy regimens have temporary effects with various side effects. Objective: The objective of this study was to assess the efficacy of a new chemotherapy regimens in advanced stages of MF. This regimens takes advantage of synergistic effect of methotrexate and fluorouracil and also uses leucovorin to reduce side effects of methotrexate. Patients and Methods: Five patients with advanced stages of MF (Stage IIB and higher) were treated with several courses of this chemotherapy regimens in a quasi experimental study. Results: Four patients responded partially one responded completely to this regimen but all of them relapsed after tapering the treatment. All of them tolerated the drugs well and no serious side effects were observed. Tumoral lesions showed better response. Conclusion: Although this chemotherapy regimen, similar to other regimens, only had temporary and palliative effects, it was tolerated well without serious side effects.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

Methotrexate-induced cutaneous ulceration has rarely been reported in patients with mycosis fungoides. We report 4 patients with mycosis fungoides who developed cutaneous ulceration as an initial manifestation of methotrexate toxicity. Methotrexate dose at the time of ulceration ranged from 10-60 mg. All 4 patients were erythrodermic, which may have predisposed them to this toxic effect. It is ...

full text

Mycosis fungoides restricted to the palms: efficacy of methotrexate.

A 73-year-old patient was seen in 1995 for scaly hyperkeratotic plaques that had appeared 3 years previously on the palms, with lesions of dry pulpitis on 2 fingers (Fig 1). The plaques were well-defined and had a main diameter of 2 – 5 cm. Topical treatments (high-potency corticosteroids, emollients, keratolytic agents) made no significant improvement. Pruritus was moderate to severe. No other...

full text

Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.

The purpose of the present study was to investigate the association between performance status (PS) and mean dose of irinotecan (CPT-11) in patients with recurrent advanced colorectal cancer relapsing after 5-fluorouracil and leucovorin chemotherapy. Patients who had completed their last chemotherapy course with 5-fluorouracil and leucovorin for at least 6 weeks and progressed were included. Ba...

full text

A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.

PURPOSE Irinotecan, in combination with leucovorin/5-fluorouracil (FU) or with cisplatin, is known to be active for treating advanced gastric cancer (AGC). This pilot study evaluated a novel three-drug combination of irinotecan, leucovorin/FU and cisplatin as a first-line treatment of AGC. The primary endpoint was to assess the feasibility in anticipation of conducting a larger phase II study. ...

full text

Phase I Trial of 7V-(Phosphonacetyl)-L-aspartate, Methotrexate, and 5-Fluorouracil with Leucovorin Rescue in Patients with Advanced Cancer1

Based on an animal model to improve the antitumor activity of 5fluorouracil (FUra), a Phase I study of A/-(phosphonacetyl)-i .-aspartate, methotrexate, FUra, and leucovorin was conducted on 44 patients. Meth otrexate was given in an intermediate dose (250 mg/nr) to overcome potential drug resistance, and ¿V-(phosphnnacetyl)-i.-aspartatewas given at a low dose (250 mg/nr') in order to allow esc...

full text

Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.

Based on an animal model to improve the antitumor activity of 5-fluorouracil (FUra), a Phase I study of N-(phosphonacetyl)-L-aspartate, methotrexate, FUra, and leucovorin was conducted on 44 patients. Methotrexate was given in an intermediate dose (250 mg/m2) to overcome potential drug resistance, and N-(phosphonacetyl)-L-aspartate was given at a low dose (250 mg/m2) in order to allow escalatio...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 2

pages  21- 25

publication date 2001-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023